Tech Company Financing Transactions

Otologic Pharmaceutics Funding Round

On 4/4/2014, Otologic Pharmaceutics announced $4.1 million in Series A funding from Accele BioPharma, i2e Enterprise Oklahoma Fund and Oklahoma Life Sciences Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

865 Research Pkwy. 400
Oklahoma City, OK 73104
USA

Phone

(405) 319-8165

Website

www.otologicpharmaceutics.com

Email Address

[email protected]

Overview

Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Clayton Duncan

        

Chief Medical Officer

Richard Kopke

        

Chief Scientific Officer

Robert Floyd

        

Browse more venture capital transactions:

Prev: 4/4/2014: GemShare venture capital transaction
Next: 4/4/2014: Newlight Technologies venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary